1. Home
  2. GBIO vs UTSI Comparison

GBIO vs UTSI Comparison

Compare GBIO & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • UTSI
  • Stock Information
  • Founded
  • GBIO 2016
  • UTSI 1991
  • Country
  • GBIO United States
  • UTSI China
  • Employees
  • GBIO N/A
  • UTSI N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • UTSI Telecommunications Equipment
  • Sector
  • GBIO Health Care
  • UTSI Telecommunications
  • Exchange
  • GBIO Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • GBIO 29.5M
  • UTSI 24.9M
  • IPO Year
  • GBIO 2020
  • UTSI 2000
  • Fundamental
  • Price
  • GBIO $4.15
  • UTSI $2.50
  • Analyst Decision
  • GBIO Strong Buy
  • UTSI
  • Analyst Count
  • GBIO 4
  • UTSI 0
  • Target Price
  • GBIO $73.33
  • UTSI N/A
  • AVG Volume (30 Days)
  • GBIO 210.0K
  • UTSI 6.0K
  • Earning Date
  • GBIO 08-06-2025
  • UTSI 09-04-2025
  • Dividend Yield
  • GBIO N/A
  • UTSI N/A
  • EPS Growth
  • GBIO N/A
  • UTSI N/A
  • EPS
  • GBIO N/A
  • UTSI N/A
  • Revenue
  • GBIO $24,556,000.00
  • UTSI $10,878,000.00
  • Revenue This Year
  • GBIO N/A
  • UTSI N/A
  • Revenue Next Year
  • GBIO N/A
  • UTSI N/A
  • P/E Ratio
  • GBIO N/A
  • UTSI N/A
  • Revenue Growth
  • GBIO 146.47
  • UTSI N/A
  • 52 Week Low
  • GBIO $3.00
  • UTSI $1.84
  • 52 Week High
  • GBIO $34.35
  • UTSI $3.22
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 53.64
  • UTSI 47.68
  • Support Level
  • GBIO $4.22
  • UTSI $2.39
  • Resistance Level
  • GBIO $5.10
  • UTSI $2.63
  • Average True Range (ATR)
  • GBIO 0.62
  • UTSI 0.08
  • MACD
  • GBIO 0.00
  • UTSI -0.01
  • Stochastic Oscillator
  • GBIO 30.14
  • UTSI 27.50

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

Share on Social Networks: